CDK4/6 inhibitors (CDK4/6i), namely, ribociclib and palbociclib, but, in particular, abemaciclib, turned out to be particularly effective in luminal BC but not in other BC subtypes [21,22]. This evidence concerns the gene CDK4 and breast cancer.